S-1: Bio-Path Holdings Announces Public Offering of Common Stock and Warrants

Bio-Path Holdings, Inc. plans to offer up to 1,152,073 shares of common stock, pre-funded warrants, and common warrants to purchase up to 2,304,146 shares of common stock.

Summary

• Bio-Path Holdings, a clinical and preclinical-stage oncology-focused company, is conducting a best efforts public offering of common stock and warrants.
• The offering includes up to 1,152,073 shares of common stock, pre-funded warrants for up to 1,152,073 shares, and common warrants for up to 2,304,146 shares.
• The combined public offering price is assumed to be $6.51 per share and accompanying warrant, based on the last reported sale price on March 6, 2024.
• Pre-funded warrants are offered to investors whose purchase would result in beneficial ownership exceeding 4.99% or 9.99% of outstanding common stock.
• The exercise price for pre-funded warrants is $0.001, while the exercise price for common warrants will be a percentage of the combined offering price.
• The offering is managed by Roth Capital Partners, LLC, on a best efforts basis, with no minimum offering amount.
• The company plans to use the net proceeds for working capital and general corporate purposes.
• The company’s lead drug candidate, prexigebersen, is in a Phase 2 clinical trial for acute myeloid leukemia (AML).
• Interim data from the trial shows promising results, with high CR/CRi rates in both newly diagnosed and refractory/relapsed AML patients.
• The company is also developing other drug candidates, including BP1002 for lymphoma and CLL, and BP1003 for pancreatic cancer, NSCLC, and AML.
• BP1001-A is in a Phase 1/1b clinical trial for advanced or recurrent solid tumors.

Sentiment

Score: 7

Explanation: The overall sentiment is cautiously optimistic. The promising clinical trial results for prexigebersen and the progress of other drug candidates are positive factors. However, the company's financial situation, including the accumulated deficit and the need for additional capital, warrants caution. The 'best efforts' nature of the offering also adds an element of uncertainty to the company's ability to secure the needed funding.

Positives

• Interim Phase 2 clinical trial data for prexigebersen shows promising CR/CRi rates of 86% in newly diagnosed AML patients and 57% in refractory/relapsed AML patients, exceeding current treatment rates.
• Successful completion of the first dose cohorts in Phase 1 trials for BP1002 (lymphoma and CLL) and Phase 1/1b trial for BP1001-A (solid tumors) with no dose-limiting toxicities.
• Preclinical studies suggest BP1002 in combination with decitabine is efficacious in venetoclax-resistant leukemia and lymphoma cells.
• Preclinical models show BP1003 inhibits cell viability and STAT3 protein expression in NSCLC and AML cell lines and enhances the efficacy of gemcitabine in pancreatic cancer.
• The company has a diverse pipeline of drug candidates targeting multiple cancer indications.

Negatives

• The company has an accumulated deficit of $107.6 million and has not generated any revenue to date.
• The company has a limited cash balance of $1.1 million as of December 31, 2023, and will require additional funding to continue operations.
• The offering is a best efforts offering with no minimum amount of securities required to be sold, meaning the company may raise significantly less than the projected $6.8 million.
• There is no established public trading market for the warrants, limiting their liquidity.

Risks

• The company faces substantial competition in the pharmaceutical and biotechnology industry.
• The company’s drug candidates are in early stages of development and may not prove safe or effective.
• The company may not be able to obtain regulatory approval for its drug candidates.
• The company may not be able to raise additional capital when needed.
• The market price of the company’s common stock is volatile and may decline.
• Investors will experience immediate and substantial dilution in the net tangible book value per share of common stock purchased in this offering.

Future Outlook

The company expects to use the net proceeds from the offering for working capital and general corporate purposes, including continued development of its drug candidates. The company is pursuing FDA expedited programs for prexigebersen and evaluating expansion of the Phase 2 trial in Europe. The company also plans to apply its DNAbilize technology to new disease targets and explore collaborations and licensing arrangements.

Industry Context

The company is operating in the competitive oncology drug development space, where there is a significant need for effective treatments with fewer side effects. The company’s DNAbilize technology offers a novel approach to drug delivery and protein inhibition, potentially addressing unmet needs in various cancer indications.

Comparison to Industry Standards

• The CR/CRi rate of 86% for newly diagnosed AML patients treated with prexigebersen, decitabine, and venetoclax is significantly higher than the 62-71% rate observed with decitabine and venetoclax alone.
• The CR/CRi rate of 57% for refractory/relapsed AML patients treated with the triple combination is also higher than the 21% rate for decitabine and venetoclax and the 42-52% rate for relapsed/refractory AML patients treated with the same combination.

Stakeholder Impact

• Existing shareholders will experience dilution due to the issuance of new shares.
• The offering's success will impact the company's ability to fund its operations and develop its drug candidates, affecting the interests of shareholders, employees, and potential future patients.

Next Steps

• Complete the public offering of common stock and warrants.
• Continue the Phase 2 clinical trial for prexigebersen in AML, potentially expanding it to Europe.
• Progress BP1002 through Phase 1 trials for lymphoma and CLL.
• Complete IND-enabling studies for BP1003 and initiate a Phase 1 trial.
• Continue the Phase 1/1b trial for BP1001-A in solid tumors.
• Explore out-licensing or partnering opportunities for DNAbilize technology-based products.
• Develop new drug candidates for cancer and other diseases.

Key Dates

Keywords

RNAi, Nanoparticle, Drug Development, Oncology, Cancer Treatment, Acute Myeloid Leukemia, Lymphoma, Pancreatic Cancer, Clinical Trials, Biotechnology, Pharmaceuticals, DNAbilize, Prexigebersen, BP1002, BP1003, BP1001-A, Public Offering, Warrants